Publications by authors named "T D Gauntner"
Article Synopsis
- Metastatic renal cell carcinoma (mRCC) is a complex disease with varying progression and treatment options, but these treatments can come with side effects.
- Active surveillance (AS) is being considered as a strategy to postpone the initiation of more toxic treatments for certain patients.
- The article reviews existing research on managing mRCC, highlighting the appropriate use of AS in patients who are asymptomatic and haven't yet received systemic therapy, noting that the median period on AS before starting treatment can be between 14 to 60 months.
Article Synopsis
- * Current research suggests that conventional immunotherapies have a sex bias, showing that males respond better while females face more severe side effects from treatments like immune checkpoint blockade.
- * The article discusses biological factors contributing to these sex disparities, including the roles of sex hormones, genetic influences from chromosomes, and other epigenetic mechanisms in immune and tumor cells, signaling a need for more integrated studies in immuno-oncology.
Loss of the Y chromosome (LOY) is observed in multiple cancer types, including 10-40% of bladder cancers, but its clinical and biological significance is unknown. Here, using genomic and transcriptomic studies, we report that LOY correlates with poor prognoses in patients with bladder cancer. We performed in-depth studies of naturally occurring LOY mutant bladder cancer cells as well as those with targeted deletion of Y chromosome by CRISPR-Cas9.
View Article and Find Full Text PDFArticle Synopsis
- * The study analyzed data from 377 patients who received stem cell transplants from matched sibling donors to determine the effects of different CD34 cell doses.
- * Results suggest that aiming for a CD34 cell dose of at least 7.5 × 10^6/kg can lead to better overall survival rates after five years while acknowledging the potential for increased chronic GVHD.